Dapagliflozin Granted Priority Review for Adults With Heart Failure Dapagliflozin Granted Priority Review for Adults With Heart Failure
The application for the SGLT2 inhibitor is based on the results from the landmark phase 3 DAPA-HF trial.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - January 8, 2020 Category: Cardiology Tags: Diabetes & Endocrinology News Source Type: news

Farxiga granted FDA Priority Review for patients with heart failure with reduced ejection fraction
AstraZeneca today announced the US Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) and granted Priority Review for Farxiga (dapagliflozin) to reduce the risk of cardiovascular (CV) death or the worsening of heart failure (HF) in adults with heart failure with reduced ejection fraction (HFrEF) with and without type-2 diabetes (T2D). (Source: World Pharma News)
Source: World Pharma News - January 6, 2020 Category: Pharmaceuticals Tags: Featured AstraZeneca Business and Industry Source Type: news

AHA Names Top Heart Disease, Stroke Research Advances of 2019 AHA Names Top Heart Disease, Stroke Research Advances of 2019
A watch that detects atrial fibrillation, prescription fish oil for CV risk reduction, and the promise of dapagliflozin in HF are among the major advances for 2019, says the American Heart Association.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - January 2, 2020 Category: Cardiology Tags: Cardiology News Source Type: news

Dec 6, 2019 This Week in Cardiology Dec 6, 2019 This Week in Cardiology
Vernakalent, CV death in cancer patients, dapagliflozin, and sacubitril/valsartan are the topics Dr. John Mandrola discusses in this week's podcast.theheart.org on Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 6, 2019 Category: Consumer Health News Tags: Cardiology Commentary Source Type: news

Making Room for New Drugs for Heart Failure Making Room for New Drugs for Heart Failure
Drs Ileana Pi ñ a and Mary Walsh discuss the latest HF updates from the American Heart Association Scientific Sessions and ask where dapagliflozin and sacubitril/valsartan will fit in the armamentarium.theheart.org on Medscape (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - November 26, 2019 Category: Cardiology Tags: Cardiology Commentary Source Type: news

DAPA-HF: Dapagliflozin Benefits Regardless of Age, HF Severity DAPA-HF: Dapagliflozin Benefits Regardless of Age, HF Severity
The SGLT2 inhibitor showed about the same effect on its clinical primary end point in the very elderly and across all degrees of symptom status at baseline in two new analyses.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - November 25, 2019 Category: Cardiology Tags: Cardiology News Source Type: news

FDA OKs Diabetes Drug for Type 2 Heart Failure Risk
The FDA granted a new use for diabetes drug Farxiga (dapagliflozin): to reduce the risk of hospitalization for heart failure in adults who have type 2 diabetes and established heart disease or risk factors for it. (Source: WebMD Health)
Source: WebMD Health - October 22, 2019 Category: Consumer Health News Source Type: news

FDA OKs Dapagliflozin to Reduce HF Hospitalization in Diabetes FDA OKs Dapagliflozin to Reduce HF Hospitalization in Diabetes
Dapagliflozin (Farxiga, AstraZeneca) has additionally been approved in the US for reducing hospitalization for heart failure (HF) in adults with type 2 diabetes and other cardiovascular risk factors.FDA Approvals (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - October 21, 2019 Category: Cardiology Tags: Diabetes & Endocrinology News Alert Source Type: news

FDA Approves Farxiga (dapagliflozin) to Reduce the Risk of Hospitalization for Heart Failure in Patients with Type 2 Diabetes
21 October 2019 -- AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved Farxiga (dapagliflozin) to reduce the risk of hospitalization for heart failure (hHF) in adults with type 2 diabetes (T2D) and established... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - October 21, 2019 Category: Drugs & Pharmacology Source Type: news

What Do You Think of Dapagliflozin for Heart Failure? What Do You Think of Dapagliflozin for Heart Failure?
Recent trial results indicate that the diabetes drug provides substantial benefits for heart failure patients, even those without diabetes.Medscape Reader Polls (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - October 2, 2019 Category: Cardiology Tags: Cardiology News Source Type: news

Dapagliflozin Lowers Risk for Worsening Heart Failure
MONDAY, Sept. 23, 2019 -- For patients with heart failure and reduced ejection fraction, dapagliflozin is associated with a lower risk for worsening heart failure or death from cardiovascular causes, regardless of the presence of type 2 diabetes,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 23, 2019 Category: Pharmaceuticals Source Type: news

EU Panel Votes to Expand Dulaglutide Indication Based on REWIND EU Panel Votes to Expand Dulaglutide Indication Based on REWIND
The panel also recommends approval of Qtrilmet, a fixed-dose combination of metformin hydrochloride/saxagliptin/dapagliflozin for treatment of type 2 diabetes.International Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 20, 2019 Category: Consumer Health News Tags: Diabetes & Endocrinology News Alert Source Type: news

Sep 20 2019 This Week in Cardiology Sep 20 2019 This Week in Cardiology
The polypill, dapagliflozin, TAVR, and video games are discussed by John Mandrola, MD, in this week ’ s podcast.theheart.org on Medscape (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - September 20, 2019 Category: Cardiology Tags: Cardiology Commentary Source Type: news

Diabetes drug also treats heart failure, researchers say
Dapagliflozin was found to cut death rates and hospital stays and improve patient's quality of life. (Source: BBC News | Health | UK Edition)
Source: BBC News | Health | UK Edition - September 19, 2019 Category: Consumer Health News Source Type: news

DAPA-HF Published:'Stunning Consistent Benefit With Dapagliflozin'DAPA-HF Published:'Stunning Consistent Benefit With Dapagliflozin '
Publication of trial reinforces"remarkably consistent" benefits of the SGLT2 inhibitor dapagliflozin in patients with heart failure, with or without diabetes,"bolsters confidence in the conclusions."Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 19, 2019 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news

A New Drug for HF? DEFINE-HF Bolsters Dapagliflozin Cardio Cred A New Drug for HF? DEFINE-HF Bolsters Dapagliflozin Cardio Cred
On the heels of the DAPA-HF outcomes trial, DEFINE-HF shows adding the SGLT-2 inhibitor to standard meds improved other endpoints heart failure patients care about, whether or not they had diabetes.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - September 18, 2019 Category: Cardiology Tags: Cardiology News Source Type: news

FDA grants Fast Track designation for Farxiga in heart failure
AstraZeneca announced that the US Food and Drug Administration (FDA) has granted Fast Track designation for the development of Farxiga (dapagliflozin) to reduce the risk of cardiovascular (CV) death, or the worsening of heart failure, in adults with heart failure with reduced ejection fraction (HFrEF) or preserved ejection fraction (HFpEF). (Source: World Pharma News)
Source: World Pharma News - September 17, 2019 Category: Pharmaceuticals Tags: Featured AstraZeneca Business and Industry Source Type: news

Will DAPA-HF Turn the Tide on Heart Failure? Will DAPA-HF Turn the Tide on Heart Failure?
The term gamechanger is overused but may be appropriate for the DAPA-HF trial on the SGLT2 inhibitor dapagliflozin in patients with heart failure and reduced ejection fraction. Medical conservative John Mandrola, MD, was impressed.theheart.org on Medscape (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - September 6, 2019 Category: Cardiology Tags: Cardiology Expert Column Source Type: news

Diabetes treatment also reduces heart failure risk
Type 2 diabetes treatment, dapagliflozin, is also effective for reducing the risk of heart failure, according to research presented at the European Society of Cardiology conference in Paris.Times (Source: Society for Endocrinology)
Source: Society for Endocrinology - September 2, 2019 Category: Endocrinology Source Type: news

Dapagliflozin: New HF Therapy, Even Sans Diabetes Dapagliflozin: New HF Therapy, Even Sans Diabetes
Significant reductions in heart failure events and mortality associated with the diabetes drug in the randomized trial point to a new era in the treatment of heart failure, experts say.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - September 2, 2019 Category: Cardiology Tags: Cardiology News Source Type: news

U.S. FDA Gives Fast Track Status to Dapagliflozin for Patients With Chronic Kidney Disease U.S. FDA Gives Fast Track Status to Dapagliflozin for Patients With Chronic Kidney Disease
AstraZeneca Plc said on Tuesday that the U.S. Food and Drug Administration has granted fast track status for the development of its diabetes drug Farxiga (dapagliflozin) to prevent heart and kidney failure in patients with chronic kidney disease (CKD), with and without diabetes.Reuters Health Information (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - August 29, 2019 Category: Intensive Care Tags: Diabetes & Endocrinology News Source Type: news

FDA grants Fast Track designation for Farxiga in chronic kidney disease
AstraZeneca today announced that the US Food and Drug Administration (FDA) has granted Fast Track designation for the development of Farxiga (dapagliflozin) to delay the progression of renal failure and prevent cardiovascular (CV) and renal death in patients with chronic kidney disease (CKD). (Source: World Pharma News)
Source: World Pharma News - August 27, 2019 Category: Pharmaceuticals Tags: Featured AstraZeneca Business and Industry Source Type: news

Aug 23 2019 This Week in Cardiology Aug 23 2019 This Week in Cardiology
TAVR, baroreflex activation for heart failure, dapagliflozin for HF, and myocardial viability are the topics discussed by John Mandrola in this week ’ s podcast.theheart.org on Medscape (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - August 23, 2019 Category: Cardiology Tags: Cardiology Commentary Source Type: news

DAPA-HF Top-Line Results: Dapagliflozin Hits Primary Outcome DAPA-HF Top-Line Results: Dapagliflozin Hits Primary Outcome
The SGLT2 inhibitor dapagliflozin provided significant and clinically meaningful reductions in heart failure outcomes, according to the sponsoring company.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - August 20, 2019 Category: Cardiology Tags: Cardiology News Source Type: news

Farxiga met primary endpoint in landmark Phase III DAPA-HF trial for the treatment of patients with heart failure
AstraZeneca today announced positive results from the landmark Phase III DAPA-HF trial which showed that Farxiga (dapagliflozin) met the primary composite endpoint with a statistically-significant and clinically-meaningful reduction of cardiovascular death or the worsening of heart failure (defined as hospitalisation or an urgent heart failure visit), compared to placebo. (Source: World Pharma News)
Source: World Pharma News - August 20, 2019 Category: Pharmaceuticals Tags: Featured AstraZeneca Business and Industry Source Type: news

Diabetes patients to be offered daily tablet to curb 'runaway' blood sugar levels
Clare Blaydon-Ellis (pictured), from Hertfordshire, has been taking Forxiga for 18 months. She says she has experienced 'very few blood sugar level problems' in that time. (Source: the Mail online | Health)
Source: the Mail online | Health - July 28, 2019 Category: Consumer Health News Source Type: news

Alembic Pharma gets tentative nod from USFDA for glycemic control drug
Quoting IQVIA sales data, the company said, Dapagliflozin Tablets, have an estimated market size of USD 1.7 billion for 12 months, ending December 2018. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - July 23, 2019 Category: Pharmaceuticals Source Type: news

Green Light for CVD Data From DECLARE in Dapagliflozin EU Label Green Light for CVD Data From DECLARE in Dapagliflozin EU Label
The EMA CHMP gives green light to change EU label for dapagliflozin (Forxiga, AstraZeneca) for type 2 diabetes to include CV outcomes data from DECLARE-TIMI 58.International Approvals (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - July 2, 2019 Category: Cardiology Tags: Diabetes & Endocrinology News Alert Source Type: news

SGLT2 Inhibitor Reduces CV, Renal Events in Type 2 Diabetes
ADA 2019 —Dapagliflozin reduced CV death, hospitalization for HF, and progression of CKD among T2DM patients with a wide distribution of baselines CVD risk in DECLARE-TIMI 58. (Source: ConsultantLive)
Source: ConsultantLive - June 17, 2019 Category: Internal Medicine Authors: Kenneth Bender, PharmD, MA Tags: Cardiovascular Disease Diabetes Diabetes Type 2 Source Type: news

More DECLARE-TIMI: Robust Renal Effects of Dapagliflozin More DECLARE-TIMI: Robust Renal Effects of Dapagliflozin
A new analysis from the landmark trial with the diabetes drug dapagliflozin shows a large, robust effect on important kidney outcomes. Accumulating data support'leading role for SGLT2 inhibitors,'in diabetes.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - June 11, 2019 Category: Cardiology Tags: Diabetes & Endocrinology News Source Type: news

Qternmet XR (Dapagliflozin, Saxagliptin, and Metformin Hydrochloride) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - May 8, 2019 Category: Drugs & Pharmacology Source Type: news

Qternmet XR Combinations Approved for Type-2 Diabetes
New drug combines dapagliflozin, saxagliptin, and metformin. (Source: ConsultantLive)
Source: ConsultantLive - May 6, 2019 Category: Internal Medicine Authors: Drew Boxler Tags: Diabetes Diabetes Type 2 Latest e-News New Products The Latest Source Type: news

FDA Approves Qternmet XR (dapagliflozin, saxagliptin and metformin hydrochloride) for Type 2 Diabetes
 3 May 2019 -- The US Food and Drug Administration (FDA) has approved Qternmet XR (dapagliflozin, saxagliptin and metformin hydrochloride) extended release tablets as an oral adjunct treatment to diet and exercise to improve glycaemic control... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - May 3, 2019 Category: Drugs & Pharmacology Source Type: news

Dapagliflozin Improves Glucose Outcomes in Type 1 Diabetes
FRIDAY, April 26, 2019 -- In patients with type 1 diabetes, treatment with dapagliflozin for 24 weeks improves time in range, mean glucose, and glycemic variability, according to a study published online April 9 in Diabetes Care. Chantal Mathieu,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 26, 2019 Category: Pharmaceuticals Source Type: news

Less HF Hospitalization on Dapagliflozin in Diabetes at Any LVEF Less HF Hospitalization on Dapagliflozin in Diabetes at Any LVEF
Survivals gains were seen in DECLARE-TIMI 58 only in those with low ejection fractions. Preliminary, but it suggests an SGLT2 inhibitor benefit in a range of people with diabetes and heart failure.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - April 4, 2019 Category: Cardiology Tags: Cardiology News Source Type: news

Forxiga approved in Japan for type-1 diabetes
The Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Forxiga (dapagliflozin) as an oral adjunct treatment to insulin for adults with type-1 diabetes (T1D). The approval is based on data from the Phase III DEPICT clinical programme and a dedicated trial in Japanese patients (D1695C00001). (Source: World Pharma News)
Source: World Pharma News - March 27, 2019 Category: Pharmaceuticals Tags: Featured AstraZeneca Business and Industry Source Type: news

ACC.19: 3 Studies in Cardioprotection
Dapagliflozin, icosapent ethyl, and bempedoic acid were found to reduce clinical or surrogate CV endpoints in studies presented at ACC.19, March 16-18, in New Orleans, LA. (Source: ConsultantLive)
Source: ConsultantLive - March 25, 2019 Category: Internal Medicine Authors: Veronica Hackethal, MD Tags: Cardiovascular Disease Source Type: news

EU approves AstraZeneca's drug for adjunct use in Type-1 diabetes
British drugmaker AstraZeneca Plc said on Monday the European Commission approved its diabetes drug Forxiga for use as an oral supplement to insulin in adults with a rare type of the disease. (Source: Reuters: Health)
Source: Reuters: Health - March 25, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

Diabetes drug effective against heart failure in wide spectrum of patients
The cardiovascular benefits of the diabetes drug dapagliflozin extend across a wide spectrum of patients and are especially pronounced in those with reduced ejection fraction, a measure of the heart's pumping ability indicative of poor heart functioning, according to research presented at the American College of Cardiology's 68th Annual Scientific Session. (Source: World Pharma News)
Source: World Pharma News - March 18, 2019 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

FDA Approves Expanded Uses for Type 2 Diabetes Drugs FDA Approves Expanded Uses for Type 2 Diabetes Drugs
Dapagliflozin has been okayed for patients with moderate renal impairment, and single-injection GLP-1 agonist/basal insulin combos Soliqua and Xultophy are now approved for earlier intensification of therapy.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 1, 2019 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news

Go ahead for first add-on tablet to insulin treatment for type 1 diabetes
European regulator recommends dapagliflozin for those with poor blood glucose control despite best efforts Related items fromOnMedica Use of DPP-4 inhibitors associated with increased risk of IBD Adding insulin to metformin linked to higher mortality Draft diabetes guidance too heavily focused on cost, protests industry MHRA tightens licence restrictions on valproate for women Withdrawn valsartan meds not linked to short-term cancer risk (Source: OnMedica Latest News)
Source: OnMedica Latest News - February 5, 2019 Category: UK Health Source Type: news

Forxiga receives positive EU CHMP opinion for the treatment of adults with type-1 diabetes
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended a new indication for the marketing authorisation of Forxiga (dapagliflozin), after adopting a positive opinion for use as an oral adjunct treatment to insulin in adults with type-1 diabetes (T1D). (Source: World Pharma News)
Source: World Pharma News - February 4, 2019 Category: Pharmaceuticals Tags: Featured AstraZeneca Business and Industry Source Type: news

EU Panel Backs Dapagliflozin for Some With Type 1 Diabetes EU Panel Backs Dapagliflozin for Some With Type 1 Diabetes
If approved, it would be the first oral add-on to insulin worldwide, but could only be used in patients in whom risk of diabetic ketoacidosis can be properly mitigated.International Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 1, 2019 Category: Consumer Health News Tags: Diabetes & Endocrinology News Alert Source Type: news

Harms of Treatment; Height and Longevity: It's PodMed Double T! (with audio)
(MedPage Today) -- This week's topics also include when to start a common Parkinson's disease drug and dapagliflozin's effects on heart risks (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - January 26, 2019 Category: Cardiology Source Type: news

Effect of Dapagliflozin in T2D Patients With Stages 3b-4 CKD Effect of Dapagliflozin in T2D Patients With Stages 3b-4 CKD
Is dapagliflozin an effective therapeutic option for patients with type 2 diabetes and chronic kidney disease? How does it impact clinical outcomes in these patients?Nephrology Dialysis Transplantation (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 22, 2018 Category: Consumer Health News Tags: Nephrology Journal Article Source Type: news

AHA: Dapagliflozin Noninferior to Placebo for MACE in T2DM
TUESDAY, Nov. 13, 2018 -- Treatment with dapagliflozin is noninferior to placebo for major adverse cardiovascular events (MACE) among patients with type 2 diabetes with or at risk for atherosclerotic cardiovascular disease, according to a study... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 13, 2018 Category: Pharmaceuticals Source Type: news

AHA: Mixed Results with Dapagliflozin in T2D Patients
(MedPage Today) -- SGLT2 inhibitor didn't change MACE rate, but did result in other positive CV outcomes (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - November 10, 2018 Category: Cardiology Source Type: news

DECLARE-TIMI 58: Dapagliflozin Cuts Heart Failure in Diabetes DECLARE-TIMI 58: Dapagliflozin Cuts Heart Failure in Diabetes
The trial did not show a significant reduction in major adverse cardiovascular events but does extend the heart failure benefits of SGLT2 inhibitors to the primary prevention population.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 10, 2018 Category: Consumer Health News Tags: Cardiology News Source Type: news

Diabetes Drug, Farxiga, Might Also Ease Heart Failure Risks
SATURDAY, Nov. 10, 2018 -- The diabetes drug Farxiga might do double-duty for patients, helping to ward off another killer, heart failure, new research shows. Type 2 diabetics who took Farxiga (dapagliflozin) saw their odds of hospitalization for... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - November 10, 2018 Category: General Medicine Source Type: news

Diabetes Drug Farxiga (dapagliflozin) Might Also Ease Heart Failure Risks
SATURDAY, Nov. 10, 2018 -- The diabetes drug Farxiga might do double-duty for patients, helping to ward off another killer, heart failure, new research shows. Type 2 diabetics who took Farxiga (dapagliflozin) saw their odds of hospitalization for... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - November 10, 2018 Category: General Medicine Source Type: news